Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telbivudine or lamivudine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telbivudine and lamivudine are both oral antiviral agents classified as nucleoside analog reverse transcriptase inhibitors. They are primarily used for the treatment of chronic hepatitis B virus (HBV) infection. Telbivudine is an L-nucleoside structurally related to lamivudine and selectively inhibits HBV DNA polymerase by causing chain termination during viral DNA synthesis. Lamivudine also inhibits HBV DNA polymerase through a similar mechanism. Both drugs suppress viral replication but differ in efficacy and resistance profiles; telbivudine has demonstrated superior virological response rates compared to lamivudine in clinical trials but may be associated with higher rates of creatinine kinase elevation[1][2][3]. Both drugs have been studied for use in pregnant women with chronic HBV to prevent mother-to-child transmission[4].
- Brand names
- SebivoTyzekaEpivir
- Other names
- LdTLAM
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on telbivudine or lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telbivudine or lamivudine.